MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis

Phase 2
Completed
Conditions
Aggressive Periodontitis
Residual Disease
Interventions
Procedure: Open flap debridement
Other: Placebo
Dietary Supplement: Omega-3 polyunsaturated fatty acids
Drug: Aspirin
First Posted Date
2017-03-28
Last Posted Date
2020-11-17
Lead Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho
Target Recruit Count
34
Registration Number
NCT03093207
Locations
🇧🇷

College of Dentistry - São José dos Campos, Sao Paulo State University, Sao Jose dos Campos, SP, Brazil

Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis

Phase 2
Completed
Conditions
Aggressive Periodontitis
Interventions
Other: Placebo
Dietary Supplement: Omega-3 polyunsaturated fatty acids
Procedure: Full-mouth ultrasonic debridement
Drug: Aspirin
First Posted Date
2017-03-28
Last Posted Date
2021-12-28
Lead Sponsor
Universidade Estadual Paulista Júlio de Mesquita Filho
Target Recruit Count
38
Registration Number
NCT03093246
Locations
🇧🇷

College of Dentistry - São José dos Campos, Sao Paulo State University, Sao Jose dos Campos, SP, Brazil

Study of Aspirin in Patients with Vestibular Schwannoma

Phase 2
Recruiting
Conditions
Vestibular Schwannoma
Acoustic Neuroma
Neurofibromatosis 2
Interventions
Drug: Placebo
Drug: Aspirin
First Posted Date
2017-03-15
Last Posted Date
2024-11-05
Lead Sponsor
Massachusetts Eye and Ear Infirmary
Target Recruit Count
300
Registration Number
NCT03079999
Locations
🇺🇸

Stanford Otolaryngology/HNS, Stanford, California, United States

🇺🇸

University of Miami, Miami, Florida, United States

🇺🇸

University of Iowa, Iowa City, Iowa, United States

and more 3 locations

Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients

Phase 1
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2017-03-13
Last Posted Date
2017-03-13
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
90
Registration Number
NCT03078257
Locations
🇨🇳

First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Acetylsalicylic Acid Plus Intensive Blood Pressure Treatment in Patients With Unruptured Intracranial Aneurysms

Phase 3
Conditions
Unruptured Intracranial Aneurysms
Interventions
Drug: Acetylsalicylic acid
Other: intensive blood pressure control
First Posted Date
2017-02-24
Last Posted Date
2019-01-25
Lead Sponsor
Universitätsmedizin Mannheim
Target Recruit Count
776
Registration Number
NCT03063541
Locations
🇳🇱

UMCG, Groningen, Netherlands

🇳🇱

Leiden University Medical Center, Leiden, Netherlands

🇩🇪

Universitätsklinikum Münster, Münster, Germany

and more 11 locations

A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose ASA and Metformin in Stage I-III Crc Patients

Phase 2
Active, not recruiting
Conditions
Tertiary Prevention in Colon Cancer
Interventions
Other: Placebo
Drug: MET
Drug: ASA
First Posted Date
2017-02-09
Last Posted Date
2024-02-21
Lead Sponsor
Ente Ospedaliero Ospedali Galliera
Target Recruit Count
160
Registration Number
NCT03047837
Locations
🇮🇹

Medical Oncology Ente Ospedaliero Ospedali Galliera, Genova, Italy

Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting

Phase 4
Conditions
Coronary Artery Disease
Aspirin
Interventions
First Posted Date
2017-02-09
Last Posted Date
2017-02-09
Lead Sponsor
Medinet Heart Centre
Target Recruit Count
300
Registration Number
NCT03049085
Locations
🇵🇱

Medinet Heart Centre, Nowa Sol, Lubuskie, Poland

Aspirin in Asymmetrically Intrauterine Growth

Phase 2
Completed
Conditions
Intrauterine Growth Restriction Asymmetrical
Interventions
First Posted Date
2017-01-31
Last Posted Date
2017-01-31
Lead Sponsor
Assiut University
Target Recruit Count
60
Registration Number
NCT03038607
Locations
🇪🇬

Women Health Hospital - Assiut university, Assiut, Egypt

Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty

Phase 4
Withdrawn
Conditions
PE - Pulmonary Thromboembolism
DVT - Deep Vein Thrombosis
Interventions
Drug: Aspirin
Device: (Post- discharge) Mechanical Compression Device
First Posted Date
2017-01-23
Last Posted Date
2017-05-12
Lead Sponsor
Washington University School of Medicine
Registration Number
NCT03027167

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

Not Applicable
Completed
Conditions
High Bleeding Risk
Coronary Artery Disease
PCI
Interventions
Drug: Aspirin
Drug: P2Y12 inhibitor
First Posted Date
2017-01-18
Last Posted Date
2021-08-20
Lead Sponsor
ECRI bv
Target Recruit Count
4579
Registration Number
NCT03023020
Locations
🇳🇱

Research Centre Dordrecht, Dordrecht, Netherlands

🇳🇱

Research Centre Enschede, Enschede, Netherlands

🇳🇱

Haga Hospital, The Hague, Netherlands

and more 135 locations
© Copyright 2025. All Rights Reserved by MedPath